These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 33704621)

  • 1. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
    Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
    Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
    Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
    Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
    Filippi AR; Bar J; Chouaid C; Christoph DC; Field JK; Fietkau R; Garassino MC; Garrido P; Haakensen VD; Kao S; Markman B; McDonald F; Mornex F; Moskovitz M; Peters S; Sibille A; Siva S; van den Heuvel M; Vercauter P; Anand S; Chander P; Licour M; de Lima AR; Qiao Y; Girard N
    ESMO Open; 2024 Jun; 9(6):103464. PubMed ID: 38833971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
    Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
    JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
    Zehentmayr F; Feurstein P; Ruznic E; Langer B; Grambozov B; Klebermass M; Hüpfel H; Feichtinger J; Minasch D; Heilmann M; Breitfelder B; Steffal C; Gastinger-Grass G; Kirchhammer K; Kazil M; Stranzl H; Dieckmann K;
    Radiother Oncol; 2024 Jul; 196():110294. PubMed ID: 38653380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
    JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
    N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data.
    Jang JY; Song SY; Shin YS; Kim HU; Choi EK; Kim SW; Lee JC; Lee DH; Choi CM; Yoon S; Kim SS
    Cancer Res Treat; 2024 Jul; 56(3):785-794. PubMed ID: 38228082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.
    Tsukaguchi A; Tamiya A; Fukuda S; Iwahashi Y; Kanaoka K; Tanaka Y; Inagaki Y; Taniguchi Y; Nakao K; Kagawa T; Matsuda Y; Okishio K
    Anticancer Res; 2024 Oct; 44(10):4517-4524. PubMed ID: 39348997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
    Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH
    Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
    Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.